These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6100181)

  • 1. Gestagens in the management of prostatic carcinoma.
    Szendröi Z
    Int Urol Nephrol; 1984; 16(4):327-35. PubMed ID: 6100181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of virginal prostatic cancer with cyproterone acetate].
    Maier U
    Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
    Varenhorst E; Wallentin L; Carlström K
    Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
    de Voogt HJ
    Prostate Suppl; 1992; 4():91-5. PubMed ID: 1533452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
    J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of serum testosterone by cyproterone acetate accompanied by an unexpected increase of calcitonin secretion capacity.
    Mulder H; Eland D; Hackeng WH; Schopman W
    J Urol; 1987 Aug; 138(2):324-5. PubMed ID: 2955132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cancers of the prostate and cyproterone acetate. Value of blood testosterone and PSA levels for treatment surveillance].
    Aubert J; Dore B; Irani J; Bon D
    J Urol (Paris); 1990; 96(8):431-5. PubMed ID: 1707083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal therapy of advanced prostatic cancer.
    Fair WR
    J Urol; 1986 Sep; 136(3):653-4. PubMed ID: 2942708
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer.
    Rost A; Schmidt-Gollwitzer M; Hantelmann W; Brosig W
    Prostate; 1981; 2(3):315-22. PubMed ID: 6458025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyproterone acetate as monotherapy in prospective randomized trials.
    de Voogt HJ
    Prog Clin Biol Res; 1990; 359():85-91; discussion 105-7. PubMed ID: 2149459
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative study of cyproterone acetate and estramustine phosphate on the plasma levels of testosterone and gonadotrophic hormones in adenocarcinoma of the prostate].
    Alfonso Sánchez M; Pérez Herrero F; Urrutia Avisrror M; Vega Wong J; Lago Montero A
    Actas Urol Esp; 1986; 10(2):111-6. PubMed ID: 2942009
    [No Abstract]   [Full Text] [Related]  

  • 12. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
    Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of prostatic cancer with cyproterone acetate].
    Maier U
    Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of cancer of the prostate. New hormonal approaches].
    Schaison G
    Pathol Biol (Paris); 1989 Feb; 37(2):118-9. PubMed ID: 2523530
    [No Abstract]   [Full Text] [Related]  

  • 15. Endocrine effects of cyproterone acetate in patients with prostatic cancer.
    Isurugi K; Fukutani K; Ishida H; Hosoi Y
    J Urol; 1980 Feb; 123(2):180-3. PubMed ID: 7354512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cyproterone acetate in prostate cancer.
    Goldenberg SL; Bruchovsky N
    Urol Clin North Am; 1991 Feb; 18(1):111-22. PubMed ID: 1825143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Varenhorst E; Wallentin L
    J Urol; 1989 Nov; 142(5):1335-6. PubMed ID: 2530361
    [No Abstract]   [Full Text] [Related]  

  • 19. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
    J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
    Boccon-Gibod L; Laudat MH; Dugue MA; Steg A
    Eur Urol; 1986; 12(6):400-2. PubMed ID: 2949980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.